Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

GSK to expand gastrointestinal cancer pipeline with $1bn IDRx acquisition

The deal includes a TKI in development for gastrointestinal stromal tumours

- PMLiVE

Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

Bayer symbol

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

- PMLiVE

Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE

Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

The neurodegenerative disease affects approximately 30,000 people in the US

Establishing Remote Work Norms – Building Company Culture Virtually

Ready to redefine remote work in pharma? The second step is establishing clear norms, processes, and expectations that resonate with your team. Dive into our series for more tips on...

Impetus Digital

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

Sanofi and Alloy Therapeutics enter central nervous system deal worth over $427m

The agreement allows Sanofi to use Alloy’s antisense platform for a central nervous system target

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

- PMLiVE

A Sparkling Achievement: Sarah Atwood Celebrated as a 2024 CPD Forty Under 40

For Sarah Atwood, MPH, the proudest moment of her incredible career in education and instructional design is happening right now. Atwood is an instructional designer with a public health lens...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links